focus -WSS

focus

author：focus 2025-09-27 19:37:30 - browse：63287

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Melinda French Gates resigns from Gates Foundation

WSS

Tome Biosciences co

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

After traumatic brain injury, life support decisions can use more time

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Artificial intelligence use in health care faces greater scrutiny in 2024

Dogs on Prozac: What pet anti

leisure time

focus

focus

Medical records are filled with copy

AMAs digital advisors table RPM coding reform proposal, again

Sports medicine is finally prioritizing gender equality

Health care needs a new profession: neuroimaging counseling

Continuity nursing helped my family in our darkest PICU moments

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Sports medicine is finally prioritizing gender equality

Here’s what’s in the FDA plan to include pregnant women in clinical trials

23andMe had bad news about my health. I wish a person had delivered it

MultiPlan and major insurers sued for alleged medical price

focus

Congress might make insulin pumps more accessible to the blind

Close Medicare's dangerous gaps in addiction treatment coverage

Bird flu in milk supply is likely coming from asymptomatic cows

Cancer researcher Catriona Jamieson is sending tumors into space

Diversity in clinical trials starts with building trust, experts say

Dogs on Prozac: What pet anti

Wikipedia

entertainment

focus

focus